출판사: Visiongain/ 출판일: 2011-12-13/ 페이지 : 151/ 가격: Single User PDF; $2461, departmental(5 Useres); $4924, Site License; $8208, Global Site License PDF; $11493
리포트의 세부사항 미래에 생체은행을 위해 지켜야 하는 것은 무엇인가? Visiongain의 리포트는 당신에게2022년까지의 이것의 잠재적인 수입과 경향을 보여준다. 의약 분야에서 생체은행에 관한 자료와 전망, 토론거리들을 찾아보아라. 지하시장과 국가수준의 시장 전체에 대한 2022년까지의 판매 전망을 찾아보아라. 우리의 연구는 당신에게 의약 리서치와 제약, 진단 부분에 적용하기 위한 사업 리서치, 분석, 의견 등을 제공할 것이다. 어떻게 생체은행 산업이 시행될 수 있는가? 예를 들어 DNA와 RNA의 저장소 등의 다른 서비스, 조직 은행, 줄기 세포보관 사업, 사적 장기 거래 은행, 상업적 생체은행, 교육적인 부분과 다른 기능들에 대한 전망을 받아보아라. 당신은 수익과 토론 거리를 얻을 수 있다. 연구 개발 신청서가 늘고 범위도 넓어지고 있다. 질병, 의약품 발명과 개발, 생체지표에 대한 이해에 있어서 생체은행의 역할에 대해 접근해 보아라. 이것을 접하게 되면 앞으로 10년간은 기술적이고 유기적인 진보, 공적인 부분과 사적인 부분, 건강관리에 도움이 될 것이다. 우리의 보고서는 Cryo-Cell International, Cord Blood America, Tissue Solutions, Asterand, ViaCord, LifebankUSA, China Cord Blood 그리고 다른 기관들과 함께한다. 이들의 활동사항과 전망을 살펴보아라.
생체은행과 생체시료저장소는 의학적 연구 개발과 인간의 건강관리에 더욱 중요한 요소가 될 것이다.
생명과학과 생명기술은 이익이 된다. 이들의 전망을 살펴보아라. Visiongain의 연구는 당신의 연구와 계산, 미팅과 프레젠테이션을 돕기 위한 자료와 분석내용 의견 등을 제공한다. 당신은 우리를 통해 당신이 원하는 답을 찾을 수 있다. 수익 전망, 시장 분배, 발전 경향, 토론과 인터뷰 리포트에서 당신은 뉴스와 관점, SWOT과 STEP 전략을 포함한 질적인 분석, 시장 분배, 성장률, 수익 전망 등을 알게 될 것이다. 당신은 72개의 도표와 차트, 여섯 개의 리서치 인터뷰를 받게 된다. 의약을 위한 생체은행의 장점 : 당신을 위한 2012-2022년 간의 기술과 시장 분석 특히, 이번 연구를 따라오면 당신은 지식과 이익을 얻을 수 있다. •전세계 시장과 지하시장의 성장 경향을 살펴보면서 2022년까지의 수익 전망을 알아보아라. •그들의 활동과 전망을 살펴보면서 의약 생체은행을 운영하는 회사들에게 다가가보아라. •미국, 일본, 독일, 프랑스, 영국, 스페인, 이탈리아, 중국과 인도 등 조직은행을 선도하는 나라들의 2022년까지의 수입 전망을 살펴보아라. •기술과 서비스 분야에서 생체은행의 발전하는 경향을 재검토해 보아라. •상업적 경과에 영향을 미치는 기업 간 들의 경쟁과 기회에 대해 조사해보아라. •과연 무엇이 산업을 자극하고 억제하는지에 대해 알아보아라. •생명 공학 부분에서 우리가 한 조사에 대한 전문가의 의견을 살펴보아라. 거기서 당신은 독립적인 예측을 통한 다량이면서 질적인 독특한 결과물을 얻게 될 것이다. 우리는 당신이 남들보다 앞서도록 도우면서 전망과 발전에 대해 분석한다. 목차
1. 임원용 요약 2. 생체은행 소개 3. 생체은행과 의약 산업 4. 생체은행 관련 시장 : 시스템, 소프트웨어, 생체은행과 관련된 소모품과 서비스 5. 2022년까지 세계의 의약 생체은행 시장 6. 조직은행 시장 7. 줄기세포 보관 사업 8. 산업 전망 9. 생체은행 분야에 대한 질적 분석 10. 우리의 조사에 의한 리서치 인터뷰 11. 결론 보고서 문의
Publisher: Visiongain/ Date: 2011-12-13 / Page : 151/ Price: Single User PDF; _$2461, departmental(5 Useres); $4924, Site License; $8208, Global Site License PDF; $11493
Report Details
What does the future hold for biobanks? Visiongain's report shows you potential revenues and trends to 2022. Find data, forecasts and discussions for biobanking in medicine.
Discover sales predictions at overall market, submarket and national levels to 2022. Our study gives you business research, analysis and opinion for applications in medical research, pharmaceuticals and diagnostics.
How will the biobanking industry perform? Receive forecasts for human tissue banking, stem cell banking, private cord banking, other services (e.g., DNA and RNA storage), commercial biobanks, academic collections and other operations. You find revenues and discussions.
R&D applications are multiplying and widening. Assess contributions of biobanks in understanding disease, drug discovery, drug development and biomarkers. This decade will result in technological and organisational progress, public and private, benefiting healthcare.
Our report discusses Cryo-Cell International, Cord Blood America, Tissue Solutions, Asterand, ViaCord, LifebankUSA, China Cord Blood and other organisations. See activities and outlooks. Biobanks and biorepositories will become more important to medical R&D and human healthcare. Biological science and technology stand to benefit. Discover the prospects.
Visiongain's study provides data, analysis and opinion aiming to help your research, calculations, meetings and presentations. You can find answers now in our work.
Revenue forecasts, market shares, developmental trends, discussions and interviews In the report you find revenue forecasting, growth rates, market shares, qualitative analyses (incl. SWOT and STEP), news and views. You receive 72 tables and charts and six research interviews. Advantages of Biobanking for Medicine: Technology and Market 2012-2022 for your work
In particular, this study gives you the following knowledge and benefits:
• Find revenue predictions to 2022 for the overall world market and submarkets, seeing growth trends • Assess companies in medical biobanking, discovering activities and outlooks
• See revenue forecasts to 2022 in leading countries for human tissue banking - US, Japan, Germany, France, UK, Spain, Italy, China and India
• Review developmental trends for biobanks - technologies and services • Investigate competition and opportunities influencing commercial results • Find out what will stimulate and restrain that industry and market • View expert opinions from our survey of that biotechnology sector.
There, you receive a distinctive mix of quantitative and qualitative work with independent predictions. We analyse developments and prospects, helping you to stay ahead.
Table of Contents 1. Executive Summary
1.1 Summary Points of this Report
1.2 Aims, Scope and Format of the Report
1.2.1 Speculative Aspects of Assessing the Biobanking Market 1.2.2 Chapter Outlines
1.3 Research and Analysis Methods 1.3.1 Human Tissue Banking Market 1.3.2 Stem Cell Banking Market 2. Introduction to Biobanking 2.1 Biobanking
2.1.1 Processes Involved in Biobanking 2.2 Biobanks: A Two-Fold Character 2.3 Key Features
2.4 Classification of Biobanks 2.4.1 Volunteer Groups
2.4.1.1 Population-Based Biobanks 2.4.1.2 Disease-Oriented Biobanks 2.4.2 Ownership or Funding Structure 2.5 Guidelines and Standards
2.5.1 Guidelines for Biobanks and Use of Biological Samples for Research 2.5.2 Industry Standards for Biobanks
2.5.3 Biobanking Processes Governed by Guidelines 2.6 Laws and Regulations for Biobank-Based Research 3. Biobanking and the Pharmaceutical Industry
3.1 Scientific and Commercial Use of Biobanking in the Pharmaceutical Industry 3.1.1 Research and Drug Development
3.1.1.1 Understanding Disease Pathways 3.1.1.2 Drug Discovery
3.1.1.3 Biomarker Discovery 3.1.2 Therapeutics
3.1.3 Clinical Trials
3.2 Biobanks Operated by Pharmaceutical Companies
4. Biobanking Associated Market: Systems, Software, Consumables and Services Associated with Biobanking
4.1 Overview
4.2 Systems/Technologies 4.2.1 Automated Liquid Handling
4.2.2 Storage
4.2.2.1 Ultra-Low Temperature Freezing 4.2.2.2 Room-Temperature Storage 4.2.3 RFID and Tagging Technologies 4.3 Software
4.3.1 Laboratory Information Management System (LIMS) 4.3.1.1 LIMS Functions
4.4 Consumables 4.5 Services
5. The World Medical Biobanking Market to 2022 5.1 Current State of the Biobanking Market 5.2 Geographical Footprint
5.3 Growing Demand for Biobank Resources 5.4 Revenue Forecast for Overall Market 5.4.1 Scope and Limitations
5.4.2 Biobanking Market, 2011-2022
5.4.2.1 Sales Forecasts for Biobanking Market, 2011-2016 5.4.2.2 Sales Forecasts for Biobanking Market, 2017-2022 5.5 Commercial Biobanks: New Resources for Research 6. Human Tissue Banking Market
6.1 Revenue Forecast for Overall Human Tissue Banking Market, 2011-2022 6.1.1 Revenue Forecast for Overall Human Tissue Banking Market, 2011-2016 6.1.2 Revenue Forecast for Overall Human Tissue Banking Market, 2017-2022
6.2 Revenue Forecasts for Human Tissue Banking Market by Type of Biobank, 2011-2022 6.2.1 Revenue Forecast for Commercial Human Tissue Banking Market, 2011-2016 6.2.2 Revenue Forecast for Commercial Human Tissue Banking Market, 2017-2022 6.2.3 Revenue Forecast for Academic & Other Human Tissue Banking Market, 2011-2016 6.2.4 Revenue Forecast for Academic & Other Human Tissue Banking Market, 2017-2022 6.3 Revenue Forecasts for Human Tissue Banking in Leading National Markets, 2011-2022 6.4 Some Commercial Participants in the Human Tissue Banking Market
6.4.1 Business Models of Companies in the Biobanking Market 6.4.2 Tissue Solutions
6.4.2.1 Overview 6.4.2.2 Global Presence 6.4.2.3 Products and Services 6.4.2.3.1 Banked Samples 6.4.2.3.2 Prospective Samples 6.4.2.3.3 Fresh Samples
6.4.2.3.4 Freshly Isolated and Primary Cells 6.4.2.3.5 Services
6.4.2.4 Strengths and Capabilities 6.4.2.5 Future Outlook
6.4.3 Asterand 6.4.3.1 Overview 6.4.3.2 Global Presence 6.4.3.3 Products and Services 6.4.3.3.1 XpressBANK 6.4.3.3.2 ProCURE 6.4.3.3.3 PhaseZERO 6.4.3.3.4 BioMAP
6.4.3.4 Asterand: Raised Barriers for New Market Entrants? 6.4.3.5 Financial Performance
6.4.3.6 Future Outlook 7. Stem Cell Banking 7.1 Overview
7.2.1 Revenue Forecast for Stem Cell Banking Market, 2011-2016 7.2.2 Revenue Forecast for Stem Cell Banking Market, 2017-2022 7.3 Stem Cell Banks for Research: High Growth Possible
7.4 Umbilical Cord Blood Banking for Stem Cells 7.4.1 Blood Banks: Private vs. Public
7.4.2 Biological Insurance: Private Blood Banking 7.4.3 Umbilical Cord Banking: The Controversies 7.4.3.1 US Oversight of Cord Blood Stem Cells
7.4.4 Revenue Forecast for Private Cord Blood Banking Market, 2011-2016 7.4.5 Revenue Forecast for Private Cord Blood Banking Market, 2017-2022 7.4.6 Companies in the Field
7.4.6.1 Cord Blood America: Looking Towards the Chinese Market 7.4.6.2 ViaCord: 145,000 Blood Units in Storage
7.4.6.3 Cryo-Cell International: The First Cord Blood Bank 7.4.6.4 Stem Cell Authority: Exclusive Stem Cells
7.4.6.5 LifebankUSA: Placenta-Cord Banking 7.4.6.6 Biogenea-Cellgenea
7.4.6.7 China Cord Blood Corp 7.4.6.8 Cryo-Save
7.4.6.9 Thermogenesis 7.5 Gene/DNA Banking 8. Industry Trends
8.1 Automated Biobanking
8.1.1 Increased Uptake of Laboratory Information Management Systems (LIMS) in Biobanking 8.1.2 Addressing Sample Storage and Tracking Issues
8.2 Green Banking
8.3 Creation of National Biobanks 8.4 HIPAA Amendments
9. Qualitative Analysis of the Biobanking Sector 9.1 Strengths
9.1.1 Wealth of Information for Genetic Research 9.1.2 Potential to Change Treatments
9.1.3 Many Governments Support Biobanking 9.2 Weaknesses
9.2.1 Quality Concerns for Some Existing Biospecimen Collections 9.2.2 Lack of Standardisation and Harmonisation of Best Practices 9.2.3 Limited Sharing and Linkage of Biobanks
9.3 Opportunities
9.3.1 Genome-Wide Association Studies (GWAS) 9.3.2 Personalised Medicine
9.3.3 Pharmacogenomics: Driving the Personalised Medicine Approach 9.4 Threats
9.4.1 Ethical and Regulatory Issues
9.4.1.1 Limitations of Informed Consent in Biobanking 9.4.1.2 Confidentiality and Security to Prevent Improper Use 9.4.2 Social and Cultural Issues
9.4.3 Ownership Issues 9.4.4 Funding
10. Research Interviews from Our Survey
10.1 Dr Morag McFarlane, Chief Scientific Officer, Tissue Solutions 10.1.1 On the Use of Biobank Samples in the Pharmaceutical Industry 10.1.2 On Commercial Aspects of Biobanking
10.1.3 On the Business of Tissue Solutions
10.1.4 On the Attractiveness of Human Tissue Banking 10.1.5 On the Future of the Biobanking Market
10.2.1 On the Importance of Biobanking in the Pharmaceutical Industry 10.2.2 On the Use of Technology in Biobanking
10.2.3 On Increased Recognition of Biobanking and Harmonisation of Samples 10.2.4 On the Use of Biobanks by the Pharmaceutical Industry
10.2.5 On Private Biobanks and Scale of Operations
10.2.6 On Commercial and Public Biobanking and Legislation 10.2.7 On the Most Attractive Segment in Commercial Biobanking 10.2.8 On the Future of Biobanking: Drivers and Challenges
10.3 Dr Piet Smet, Director, Business Development, BioStorage Technologies 10.3.1 On Defining Biorepositories and Biobanks
10.3.2 On the Services of Biostorage 10.3.3 On Main Customers for Biostorage
10.3.4 On the Importance of Biorepositories in Research and Industry 10.3.5 On Technology Use in Biobanks
10.3.6 On Increased Recognition of Biobanking and Harmonisation of Samples 10.3.7 On the Use of Biobanks by the Pharmaceutical Industry
10.3.8 On Private Biobanks and Scale of Operations
10.3.9 On Commercial and Public Biobanking and Legislation 10.3.10 On the Most Attractive Segment in Commercial Biobanking 10.3.11 On Biobanking in 2020
10.3.12 On Drivers and Challenges in the Sector
10.4 Dr Tom Hoksbergen, Marketing and Sales, SampleNavigator Laboratory Automation Systems 10.4.1 On the Services of SampleNavigator
10.4.2 On Main Customers for SampleNavigator
10.4.3 On the Importance of Biorepositories in Research and Industry 10.4.4 On Technology Use in Biobanks
10.4.5 On Increased Recognition of Biobanking and Harmonisation of Samples 10.4.6 On the Use of Biobanks by the Pharmaceutical Industry
10.4.7 On Commercial Biorepositories/Banks and Scale of Operations 10.4.8 On Commercial and Public Biobanking
10.4.9 On the Most Attractive Segment in Commercial Biobanking 10.4.10 On Biobanking in 2020
10.4.11 On Drivers and Challenges in the Sector
10.5 Mr Rob Fannon, Clinical Operations Manager, BioServe 10.5.1 On the Services of BioServe
10.5.2 On Main Customers for BioServe
10.5.3 On the Importance of Biorepositories in Research and Industry 10.5.4 On Technology Use in Biobanks
10.5.5 On Increased Recognition of Biobanking and Harmonisation of Samples 10.5.6 On the Use of Biobanks by the Pharmaceutical Industry
10.5.7 On Commercial Biorepositories/Banks and Scale of Operations 10.5.8 On Commercial and Public Biobanking
10.5.9 On the Most Attractive Segment in Commercial Biobanking 10.5.10 On Biobanking in 2020
10.5.11 On Drivers and Challenges in the Sector
10.6 Dr Frans A.L. van der Horst, Chairman, Dutch Collaborative Biobank 10.6.1 On Importance of Biorepositories in Research and Industry
10.6.2 On Increased Recognition of Biobanking and Harmonisation of Samples 10.6.3 On the Services of Dutch Collaborative Biobank
10.6.4 On Commercial Drivers for Bio-Repositories/Biobanking Market 10.6.5 On Commercial and Public Biobanking
10.6.6 On Sustaining/Recovering Costs
10.6.7 On the Most Attractive Segment in Commercial Biobanking 10.6.8 On Ethical, Legal and Social Issues in Biorepositories/Biobanks 11. Conclusions
11.1 Biobanking for Research and Therapeutics
11.2 Biobanking: The Future for Drug Discovery and Personalised Medicine 11.3 Commercial Drivers of the Biobanking Market
11.4 The Sector Has Marked Challenges, but Many Opportunities for Growth List of Tables
Table 2.1 Prominent Population-Based Biobanks, 2011 Table 2.2 Prominent Disease-Oriented Biobanks, 2011
Table 2.3 Some Guidelines and Recommendations for Biobanks, 2011
Table 2.4 Laws and Regulations for Biobank-Based Research, Consent Requirements, and Privacy/ Data Protection, 2011
Table 3.1 Some Pharmaceutical and Biotechnology Companies with In-House Biobanks, 2011 Table 4.1 Prominent Companies in the Automated Liquid Handling Market, 2011
Table 4.2 Prominent Companies in Ultra-Low Temperature Freezer Market, 2011 Table 4.3 Prominent LIMS Vendors, 2011
Table 4.4 Prominent Consumables Suppliers for Biobanking, 2011 Table 4.5 Prominent Biorepository Service Providers, 2011 Table 5.1 Estimated Number of Biobanks in Europe, 2011
Table 5.2 Biobanking Market: Grouped Revenue Forecasts, 2010-2016 Table 5.3 Biobanking Market: Grouped Revenue Forecasts, 2017-2022
Table 6.1 Human Tissue Banking Market: Overall Revenue Forecast, 2010-2016 Table 6.2 Human Tissue Banking Market: Overall Revenue Forecast, 2017-2022
Table 6.3 Human Tissue Banking Market: Revenue Forecasts by Type of Biobank, 2010-2016 Table 6.4 Human Tissue Banking Market: Revenue Forecasts by Type of Biobank, 2017-2022 Table 6.5 Human Tissue Banking Market: Revenue Forecasts for Leading National Markets, 2010-2016
Table 6.6 Human Tissue Banking Market: Revenue Forecasts for Leading National Markets, 2017-2022
Table 6.7 Some Leading Companies in the World Biobanking Market, 2011 Table 6.8 Asterand: Revenue by Segment, 2009 and 2010
Table 6.9 Asterand: Revenue by Geographical Area, 2010
Table 7.1 Stem Cell Banking Market: Overall Revenue Forecast, 2010-2016 Table 7.2 Stem Cell Banking Market: Overall Revenue Forecast, 2017-2022 Table 7.3 Prominent Stem Cell Banks Serving the Research Community, 2011 Table 7.4 Costs of Various Private Cord Blood Banks Worldwide, 2011
Table 7.5 Private Cord Blood Banking Market: Revenue Forecast, 2010-2016 Table 7.6 Private Cord Blood Banking Market: Revenue Forecast, 2017-2022 Table 7.7 Cord Blood Banking Market: Drivers and Restraints, 2012-2022 Table 7.8 Some Prominent Companies in the Cord Blood Banking Market, 2011 Table 7.9 Cryo-Cell International Revenue, 2009-2010
Table 7.10 China Cord Blood Corp Revenue and Subscribers, 2009-2010 Table 7.11 Cryo-Save Revenue and Operating Profit, 2009-2010
Table 7.12 Cryo-Save Revenue by Region, 2010
Table 9.1 SWOT Analysis of the Biobanking Market: Strengths and Weaknesses, 2012-2022 Table 9.2 SWOT Analysis of the Biobanking Market: Opportunities and Threats, 2012-2022 Table 9.3 Information for a Biobank Donor, 2011
Table 11.1 Human Tissue Biobanking Market by Country, 2010, 2016, 2019 & 2022 List of Figures
Figure 2.1 Main Processes Involved in Biobanking, 2011 Figure 2.2 Classification of Biobanks, 2011
Figure 3.1 Biobanking and Pharmaceutical Development, 2011 Figure 4.1 Biobanking, Applications and Users, 2011
Figure 4.2 Functions of LIMS, 2011
Figure 5.1 Overall Biobanking Market: Revenue Forecast, 2010-2016 Figure 5.2 Overall Biobanking Market: Revenue Forecast, 2017-2022
Figure 6.1 Human Tissue Banking Market: Overall Revenue Forecast, 2010-2016 Figure 6.2 Human Tissue Banking Market: Overall Revenue Forecast, 2017-2022 Figure 6.3 Human Tissue Banking Market: Forecast by Type of Biobank, 2010-2016 Figure 6.4 Human Tissue Banking Market: Forecast by Type of Biobank, 2017-2022 Figure 6.5 Human Tissue Banking Market: Share by Type of Biobank, 2010
Figure 6.7 World and US Human Tissue Banking Markets: Revenue Forecasts, 2010-2022 Figure 6.8 Japan, EU 5 and Other Leading Human Tissue Banking Markets: National Revenue Forecasts, 2010-2022
Figure 6.9 Human Tissue Banking: National Market Shares, 2010 Figure 6.10 Human Tissue Banking: National Market Shares, 2016 Figure 6.11 Human Tissue Banking: National Market Shares, 2019 Figure 6.12 Human Tissue Banking: National Market Shares, 2022 Figure 6.13 Commercial Sourcing of Biological Samples, 2011 Figure 6.14 Commercial Banking of Biological Samples, 2011 Figure 6.15 Asterand: Revenues, 2009 & 2010
Figure 6.16 Asterand: Revenue Shares by Region of Destination, 2010 Figure 6.17 Asterand: Revenue Shares by Region of Origin, 2010 Figure 7.1 Stem Cell Banking Market: Revenue Forecast, 2010-2016 Figure 7.2 Stem Cell Banking Market: Revenue Forecast, 2017-2022
Figure 7.3 Twenty-Year Storage Costs at Various Private Cord Blood Banks Worldwide, 2011 Figure 7.4 Cord Blood Banking Market: Revenue Forecast, 2010-2016
Figure 7.5 Cord Blood Banking Market: Revenue Forecast, 2017-2022 Figure 7.6 Cryo-Cell International Revenue, 2009-2010
Figure 7.7 China Cord Blood Corp Revenue and Subscribers, 2009-2010 Figure 7.8 Cryo-Save Revenue and Operating Profit, 2009-2010
Figure 7.9 Cryo-Save Revenue Shares by Region, 2010
Figure 11.1 Biobanking Market: World Sales Forecast, 2010, 2012, 2016, 2019 & 2022
